Warfarin‐Rifampin‐Gene(WARIF‐G) Interaction : A Retrospective, Genetic, Case–Control Study
Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase should overcome this interaction, most reported cases over the last 50 years have not responded even to high warfarin doses, but some have responded to modest doses. To investigate the genetic polymorphisms' impact on this unexplained interpatient variability, we performed genotyping of CYP2C9, VKORC1, and CYP4F2 for warfarin and rifampin concomitant receivers from 2016 to 2022 at Hamad Medical Corporation, Doha, Qatar. We identified and included 36 patients: 22 responders and 14 nonresponders. Warfarin‐responders were significantly more likely to have one or more warfarin‐sensitizing CYP2C9/ VKORC1 alleles than nonresponders (odds ratio = 23.2, 95% confidence interval = 3.2–195.6; P = 0.0001). The mean genetic‐based pre‐interaction calculated dose was significantly lower for responders than for nonresponders ( P < 0.001); and was negatively correlated with warfarin sensitivity index (WSI) ( r = −0.58; P = 0.0002). The median percentage time in therapeutic range and mean WSI were significantly higher in the warfarin‐sensitizing CYP2C9/ VKORC1 alleles carriers than noncarriers ( P = 0.017 and 0.0004, respectively). Whereas the warfarin‐sensitizing CYP2C9/ VKORC1 genotypes were associated with modest on‐rifampin warfarin dose requirements, the noncarriers would have required more than double these doses to respond. Warfarin‐sensitizing CYP2C9/ VKORC1 genotypes and low genetic‐based warfarin calculated doses were associated with higher warfarin sensitivity and better anticoagulation quality in patients receiving rifampin concomitantly..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Clinical Pharmacology & Therapeutics - 113(2023), 5, Seite 1150-1159 |
| Beteiligte Personen: |
Salem, Muhammad [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 the American Society for Clinical Pharmacology and Therapeutics |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1002/cpt.2871 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015400824 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015400824 | ||
| 003 | DE-627 | ||
| 005 | 20231111143230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cpt.2871 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CPT_2023_113_5.zip.xml |
| 035 | |a (DE-627)WLY015400824 | ||
| 035 | |a (WILEY)CPT2871 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Salem, Muhammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Warfarin‐Rifampin‐Gene(WARIF‐G) Interaction |b A Retrospective, Genetic, Case–Control Study |
| 264 | 1 | |c 2023 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 the American Society for Clinical Pharmacology and Therapeutics | ||
| 520 | |a Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase should overcome this interaction, most reported cases over the last 50 years have not responded even to high warfarin doses, but some have responded to modest doses. To investigate the genetic polymorphisms' impact on this unexplained interpatient variability, we performed genotyping of CYP2C9, VKORC1, and CYP4F2 for warfarin and rifampin concomitant receivers from 2016 to 2022 at Hamad Medical Corporation, Doha, Qatar. We identified and included 36 patients: 22 responders and 14 nonresponders. Warfarin‐responders were significantly more likely to have one or more warfarin‐sensitizing CYP2C9/ VKORC1 alleles than nonresponders (odds ratio = 23.2, 95% confidence interval = 3.2–195.6; P = 0.0001). The mean genetic‐based pre‐interaction calculated dose was significantly lower for responders than for nonresponders ( P < 0.001); and was negatively correlated with warfarin sensitivity index (WSI) ( r = −0.58; P = 0.0002). The median percentage time in therapeutic range and mean WSI were significantly higher in the warfarin‐sensitizing CYP2C9/ VKORC1 alleles carriers than noncarriers ( P = 0.017 and 0.0004, respectively). Whereas the warfarin‐sensitizing CYP2C9/ VKORC1 genotypes were associated with modest on‐rifampin warfarin dose requirements, the noncarriers would have required more than double these doses to respond. Warfarin‐sensitizing CYP2C9/ VKORC1 genotypes and low genetic‐based warfarin calculated doses were associated with higher warfarin sensitivity and better anticoagulation quality in patients receiving rifampin concomitantly. | ||
| 700 | 1 | |a El‐Bardissy, Ahmed |4 aut | |
| 700 | 1 | |a Elshafei, Mohamed Nabil |4 aut | |
| 700 | 1 | |a Khalil, Ahmed |4 aut | |
| 700 | 1 | |a Mahmoud, Hesham |4 aut | |
| 700 | 1 | |a Fahmi, Amr Mohamed |4 aut | |
| 700 | 1 | |a Kasem, Mohamed |4 aut | |
| 700 | 1 | |a Bader, Loulia |4 aut | |
| 700 | 1 | |a Sherbash, Mohamed |4 aut | |
| 700 | 1 | |a Elawady, Mostafa Ibrahim |4 aut | |
| 700 | 1 | |a Abdalazim, Walaa |4 aut | |
| 700 | 1 | |a Howady, Faraj |4 aut | |
| 700 | 1 | |a Elewa, Hazem |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical Pharmacology & Therapeutics |g 113(2023), 5, Seite 1150-1159 |w (DE-627)WLY003995666 |x 15326535 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2023 |g number:5 |g pages:1150-1159 |g extent:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2023 |e 5 |h 1150-1159 |g 10 | ||